Table 1.
Patient Characteristics for Discovery and PRM Validation Cohorts
| discovery cohort |
PRM validation cohort |
|||||||
|---|---|---|---|---|---|---|---|---|
| patients | normal lung (%) | benign nodule (%) | ADC (%) | P value | normal lung (%) | benign nodule (%) | ADC (%) | P value |
| N = 10 | N = 34 | N = 24 | N = 20 | N = 20 | N = 21 | |||
| age ± SD | 68.2 ± 5.8 | 56.4 ± 12.6 | 62.3 ± 7.8 | 0.043a | 56.8 ± 13.8 | 60.5 ± 13.5 | 65.6 ± 8.6 | 0.088a |
| gender | 0.616b | 0.198b | ||||||
| male | 3 (60) | 18 (53) | 10 (42) | 10 (50) | 6 (30) | 12 (57) | ||
| female | 2 (40) | 16 (47) | 14 (58) | 10 (50) | 14 (70) | 9 (43) | ||
| race | 0.792b | 0.380b | ||||||
| Caucasian | 5 (100) | 30 (88) | 20 (83) | 20 (100) | 20 (100) | 20 (95) | ||
| African American | 0 (0) | 2 (6) | 3 (13) | 0 (0) | 0 (0) | 1 (5) | ||
| other | 0 (0) | 2 (6) | 1 (4) | 0 (0) | 0 (0) | 0 (0) | ||
| nodule (mm) ± SD | N/A | 25.3 ± 27.8 | 29.4 ± 18.5 | 0.067c | N/A | 22.9 ± 18.5 | 23.8 ± 12.4 | 0.538c |
| pack years ± SD | 71.0 ± 37.5 | 37.1 ± 30.3 | 42.4 ± 19.1 | 0.080a | 27.8 ± 26.1 | 23.9 ± 33.6 | 39.8 ± 34.4 | 0.216a |
| FEV1% ± SD | 52.0 ± 24.7 | 79.0 ± 22.6 | 71.1 ± 18.8 | 0.063a | 77.3 ± 32.5 | 82.3 ± 25.0 | 69.3 ± 25.4 | 0.286a |
| ADC path stage | ||||||||
| IA-IB | 22 (92) | 17(81) | ||||||
| IIA-IIIA | 1 (4) | 4 (19) | ||||||
| IIIB-IV | 1 (4) | 0 (0) | ||||||
| benign histologies | ||||||||
| acid fast bacilli | 3 (9) | 4 (20) | ||||||
| acute inflam. | 1(3) | 0 (0) | ||||||
| benign tumor | 2 (6) | 0 (0) | ||||||
| fungal | 16 (47) | 11 (55) | ||||||
| mixed etiology | 12 (35) | 5 (25) | ||||||
a
Kruskal-Wallis test.
b
Pearson chi-square test.
c
Wilcoxon rank sum test.